3 results
Approved WMOCompleted
1. To assess the effect of odanacatib 50 mg once weekly versus placebo on lumbar spine BMD over 24 months.2. To assess the safety and tolerability of odanacatib 50 mg once weekly compared to placebo.
Approved WMOCompleted
Primary Efficacy Objective:• To evaluate the efficacy of tocilizumab (TCZ) compared to placebo, in combination with a26-week prednisone taper regimen, in patients with giant cell arteritis (GCA), as measured by the proportion of patients in…
Approved WMOCompleted
The goal of this pilot study is to assess the usability and preliminary effects on treatment outcomes of an mHealth application supplementary to SET for patients with intermittent claudication. Furthermore, we aim to determine the reliability,…